ADVERTISEMENT
company, Sterling Biotech Holdings, had survived the last eighteen months on paper and arrogance. Revenue looked respectable if you didn’t examine how often they borrowed against receivables that weren’t due for ninety days, or how many acquisitions they’d overpaid for just to keep analysts distracted. Northbridge had backstopped four of their major continue reading …
ADVERTISEMENT